Screener
Avalo Therapeutics AVTX Contingent consideration fair value adjustments
Contingent consideration fair value adjustments at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Loss from operations | (31,517) | (19,316) | (52,419) | (33,984) |
| Other (expense) income: | ||||
| Change in fair value of derivative liability | (1,010) | (2,530) | (530) | (2,150) |
| Change in fair value of contingent consideration | (6,574) | — | (6,574) | — |
| Interest income, net | 2,761 | 1,097 | 3,564 | 2,244 |
| Total other (expense) income, net | (4,823) | (1,433) | (3,540) | 94 |
| Loss before taxes | (36,340) | (20,749) | (55,959) | (33,890) |
| Income tax expense | 18 | 16 | 29 | 24 |
Item 1. Financial Statements.
FAQ
- What is Avalo Therapeutics's contingent consideration fair value adjustments?
- Avalo Therapeutics (AVTX) reported contingent consideration fair value adjustments of $6.57M in Q2 2026.
- What does contingent consideration fair value adjustments mean?
- Contingent consideration fair value adjustments
Ask your AI about Avalo Therapeutics's contingent consideration fair value adjustments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude